Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

TSXV:XRTX - Post Discussion

XORTX Therapeutics Inc > Now we have a "MAKE" but NO " BREAK" by CEO
View:
Post by SpaceLabs on Oct 14, 2021 7:13pm

Now we have a "MAKE" but NO " BREAK" by CEO

Here you "MAKE",,,,

Definition: MAKE Criteria is defined as: MAKE (major adverse kidney events) is a composite of persistent renal function decline (>25% decline in eGFR), new requirement for hemodialysis, and death. MAKE was assessed 30-, 60-, or 90-days following AKI diagnosis.

About COVID-19 and Acute Kidney Injury

Here WE "BREAK:

Early, High Uric Acid is Independently Associated with Acute Kidney Injury and Mortality in COVID-19

CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce and share the results of an American Society of Nephrology Kidney Week abstract by Dr. Steven Coca and team at Mount Sinai Hospital Network and Icahn School of Medicine, that will be published online Friday, October 15, 2021. This study was sponsored by XORTX Therapeutics Inc. and the reported findings support the provisional patent and applications filed by XORTX announced March 2020 and March 2021.

MONEY BACK and don't PLAY GAMES on NASDAQ.

 

Early, High Uric Acid is Independently Associated with Acute Kidney Injury and Mortality in COVID-19

CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce and share the results of an American Society of Nephrology Kidney Week abstract by Dr. Steven Coca and team at Mount Sinai Hospital Network and Icahn School of Medicine, that will be published online Friday, October 15, 2021. This study was sponsored by XORTX Therapeutics Inc. and the reported findings support the provisional patent and applications filed by XORTX announced March 2020 and March 2021.

 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities